PSNLPersonalis, Inc.

BTIG analyst Mark Massaro raised the firm’s price target on Tempus AI to $80 from $70 and kept a Buy rating.

Tempus AI wrote a $1.5 billion check for a genomics company most investors had never heard of, and one blockbuster clinical trial announcement just changed everything about how that deal looks.

TEM stock rose as investors connected the upbeat clinical results to Tempus’s planned $1.5 billion acquisition of Personalis, announced last month.

TEM raises its 2026 revenue outlook as oncology testing, data demand and FDA-linked pricing gains support growth and cash flow improvement.

Personalis (PSNL) delivered earnings and revenue surprises of -20.00% and +30.21%, respectively, for the quarter ended June 2026. Do the numbers hold clues to what lies ahead for the stock?

In the past week, Tempus AI, Inc. reported second-quarter 2026 results showing revenue of US$382.49 million and a swing from a net loss of US$42.84 million a year ago to net income of US$5.64 million, while also raising its full-year 2026 revenue outlook to between US$1.60 billion and US$1.61 billion. Alongside this performance, Tempus AI advanced its oncology and data ambitions through the planned acquisition of Personalis and highlighted growing diagnostics volume and new data...

Tempus AI (NASDAQ:TEM) reported second-quarter revenue growth of 22% and raised its full-year outlook, citing accelerating oncology testing volumes, expanding demand for its data and artificial intelligence offerings, and expected reimbursement benefits from newly approved diagnostic products. Reve

Tempus AI (TEM) spent three years selling someone else's cancer test. On Monday, July 20, it decided to just buy the whole thing. The AI diagnostics company agreed to acquire Personalis (PSNL) in a deal valued at $1.5 billion. The move hands Tempus full control of a test that spots cancer ...

Tempus AI’s Personalis deal puts acquisition price and growth bets in focus Tempus AI (TEM) has moved to acquire cancer testing company Personalis in a roughly $1.5 billion all stock deal, immediately putting the spotlight on valuation, integration risk, and long term growth assumptions. The agreement would fold Personalis’ minimal residual disease, or MRD, testing into Tempus AI’s precision oncology and data platform. The combined business would target a cancer monitoring market estimated at...

The deal, structured as an all-stock transaction, gives Tempus control of Personalis' NeXT Personal cancer detection test

Under the deal, Personalis’ minimal residual disease (MRD) test will be integrated into Tempus’ broader oncology portfolio.

Tempus AI (NasdaqGS:TEM) agreed to acquire cancer monitoring company Personalis in a deal valued at about US$1.5b. The transaction is focused on expanding Tempus AI's presence in minimal residual disease (MRD) testing and precision oncology. The company plans to combine Personalis' MRD technology with its existing AI driven precision oncology platform. For investors following Tempus AI, this deal highlights how central MRD testing and precision oncology have become in cancer care. Tempus AI...

Tempus will pay a 5.6% premium to integrate Personalis' cancer-testing platform into its AI-enabled oncology business.

Tempus AI pledged to buy cancer diagnostics outfit Personalis for $1.5 billion on Monday. But shares of both medtech companies skidded.

The brokerage said the acquisition strengthens Tempus AI’s precision oncology business, though near-term financials are less compelling.

Tempus AI, a healthcare tech company, is a favorite of investor Cathie Wood. Personalis does cancer testing.

Healthcare stocks declined late Monday afternoon, with the NYSE Healthcare Index shedding 1.1% and t

Tempus AI (TEM) agreed to acquire cancer test maker Personalis (PSNL) in a $1.5 billion deal that Ne

Cathie Wood Trims AMD to Fund Bigger SpaceX Bet

Tempus AI (NASDAQ:TEM) executives said the company’s planned acquisition of Personalis is intended to strengthen its position in minimal residual disease, or MRD, testing, while expanding its biopharma data and profiling capabilities. On a call with analysts, Tempus said it agreed to acquire all ou

Tempus AI (NASDAQ:TEM) will acquire Personalis (NASDAQ:PNSL) in a stock deal valued at $1.5 billion, expanding its reach in the market for tests that monitor cancer recurrence after treatment. Personalis shareholders will receive $16.25 per share, a 6% premium to Friday's closing price and a...

Tempus AI is acquiring Personalis to accelerate the development and commercialization of cancer-monitoring solutions.

Personalis stock reversed lower Friday on a rumor Merck and at least two other suitors are trying to buy the small genomics company.

Personalis has hired investment banks Centerview and TD Securities, along with law firm Cooley, to review its strategic options, according to a report in Street Insider.